# Eventide

> Eventide is a VC fund in Little Ferry backing Biotechnology, Medical and Genetics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Little Ferry, United States
- Total investments: 2
- Last investment: Jul 2018
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://Eventide.com

Eventide is a VC fund in Little Ferry focused on Biotechnology and Medical. Founded in 1971, Eventide is a leading developer and manufacturer of digital audio processing products for recording, broadcast, and live performance, as well as, digital communications products for public safety institutions. Headquartered in Little Ferry, NJ, Eventide invented the first digital logging recorder in 1989, and introduced the H3000Ultra-Harmonizer effects processor in 1987.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Genetics | 1 | 50% |
| Health Care | 1 | 50% |
| Information Technology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series E | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $85.4M | Series E | Jul 26, 2018 |  |
| Avrobio | Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure seriousdebilitating disease.Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy. | $60M | Series B | Feb 01, 2018 |  |

2 of 2 investments shown.

## Co-investors
- [Citadel](https://shizune.co/investors/profile/citadel) — VC Fund, 2 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [Brace Pharma](https://shizune.co/investors/profile/brace-pharma) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eventide invest in?

Eventide invests primarily in Biotechnology, Medical and Genetics startups, most often at Series B and Series E stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eventide last invest?

The most recent investment recorded for Eventide closed in Jul 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co